Protalix BioTherapeutics
PLX
PLX
38 hedge funds and large institutions have $8.2M invested in Protalix BioTherapeutics in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
0.22% more ownership
Funds ownership: 0.54% → 0.77% (+0.22%)
90% less call options, than puts
Call options by funds: $23K | Put options by funds: $233K
Holders
38
Holding in Top 10
–
Calls
$23K
Puts
$233K
Top Buyers
| 1 | +$1.88M | |
| 2 | +$474K | |
| 3 | +$221K | |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$156K |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$72K |
Top Sellers
| 1 | -$436K | |
| 2 | -$44.1K | |
| 3 | -$43K | |
| 4 |
Goldman Sachs
New York
|
-$12K |
| 5 |
Wolverine Trading
Chicago,
Illinois
|
-$9K |